Tie2 identifies a hematopoietic monocytes required for tumor lineage of proangiogenic vessel formation and a mesenchymal population of pericyte progenitors

被引:1007
作者
De Palma, M
Venneri, MA
Galli, R
Sergi, LS
Politi, LS
Sampaolesi, M
Naldini, L
机构
[1] San Raffaele Inst, Angiogenesis & Tumor Targeting Res Unit, I-20132 Milan, Italy
[2] San Raffaele Inst, Telethon Inst Gene Therapy, I-20132 Milan, Italy
[3] San Raffaele Inst, Stem Cell Res Inst, I-20132 Milan, Italy
[4] Hosp San Raffaele, Neuroradiol Unit, I-20132 Milan, Italy
[5] Univ Vita Salute, Sch Med, San Raffaele Inst, I-20132 Milan, Italy
关键词
D O I
10.1016/j.ccr.2005.08.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Bone marrow-derived cells contribute to tumor angiogenesis. Here, we demonstrate that monocytes expressing the Tie2 receptor (Tie2-expressing monocytes [TEMs]) (1) are a distinct hematopoietic lineage of proangiogenic cells, (2) are selectively recruited to spontaneous and orthotopic tumors, (3) promote angiogenesis in a paracrine manner, and (4) account for most of the proangiogenic activity of myeloid cells in tumors. Remarkably, TEM knockout completely prevented human glioma neovascularization in the mouse brain and induced substantial tumor regression. Besides TEMs and endothelial cells (ECs), Tie2 expression distinguished a rare population of tumor stroma-derived mesenchymal progenitors representing a primary source of tumor pericytes. Therefore, Tie2 expression characterizes three distinct cell types required for tumor neovascularization: ECs, proangiogenic cells of hematopoietic origin, and pericyte precursors of mesenchymal origin.
引用
收藏
页码:211 / 226
页数:16
相关论文
共 45 条
[1]   Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche [J].
Arai, F ;
Hirao, A ;
Ohmura, M ;
Sato, H ;
Matsuoka, S ;
Takubo, K ;
Ito, K ;
Koh, GY ;
Suda, T .
CELL, 2004, 118 (02) :149-161
[2]   The Id proteins and angiogenesis [J].
Benezra, R ;
Rafii, S ;
Lyden, D .
ONCOGENE, 2001, 20 (58) :8334-8341
[3]   Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells [J].
Biffi, A ;
De Palma, M ;
Quattrini, A ;
Del Carro, U ;
Amadio, S ;
Visigalli, I ;
Sessa, M ;
Fasano, S ;
Brambilla, R ;
Marchesini, S ;
Bordignon, C ;
Naldini, L .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (08) :1118-1129
[4]   Angiogenesis in cancer and other diseases [J].
Carmeliet, P ;
Jain, RK .
NATURE, 2000, 407 (6801) :249-257
[5]   Inflammation and cancer [J].
Coussens, LM ;
Werb, Z .
NATURE, 2002, 420 (6917) :860-867
[6]   MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis [J].
Coussens, LM ;
Tinkle, CL ;
Hanahan, D ;
Werb, Z .
CELL, 2000, 103 (03) :481-490
[7]   Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells [J].
De Palma, M ;
Venneri, MA ;
Roca, C ;
Naldini, L .
NATURE MEDICINE, 2003, 9 (06) :789-795
[8]   In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors [J].
De Palma, M ;
Venneri, MA ;
Naldini, L .
HUMAN GENE THERAPY, 2003, 14 (12) :1193-1206
[9]   Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts [J].
Direkze, NC ;
Hodivala-Dilke, K ;
Jeffery, R ;
Hunt, T ;
Poulsom, R ;
Oukrif, D ;
Alison, MR ;
Wright, NA .
CANCER RESEARCH, 2004, 64 (23) :8492-8495
[10]   Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma [J].
Galli, R ;
Binda, E ;
Orfanelli, U ;
Cipelletti, B ;
Gritti, A ;
De Vitis, S ;
Fiocco, R ;
Foroni, C ;
Dimeco, F ;
Vescovi, A .
CANCER RESEARCH, 2004, 64 (19) :7011-7021